CN108020663A - The application of urine gelsolin and its polypeptide fragment in adenocarcinoma of lung - Google Patents
The application of urine gelsolin and its polypeptide fragment in adenocarcinoma of lung Download PDFInfo
- Publication number
- CN108020663A CN108020663A CN201610952044.3A CN201610952044A CN108020663A CN 108020663 A CN108020663 A CN 108020663A CN 201610952044 A CN201610952044 A CN 201610952044A CN 108020663 A CN108020663 A CN 108020663A
- Authority
- CN
- China
- Prior art keywords
- urine
- lung
- gsn
- adenocarcinoma
- gelsolin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
Abstract
A kind of urine gelsolin (Gelsolin, GSN) of present invention offer and its application of polypeptide fragment, are specially that urine gelsolin and its polypeptide fragment are being prepared for detecting and the application in auxiliary diagnosis adenocarcinoma of lung preparation.The present invention confirms compared with normal control and patients with lung adenocarcinoma group that gelsolin low expression in the urine of patients with lung adenocarcinoma, can be used in detection and the auxiliary diagnosis of adenocarcinoma of lung by studying.The present invention play urine specimen obtain it is noninvasive, can on a large scale repeated sampling, preserve convenient advantage, utilize urine specimen detection gelsolin and its polypeptide fragment.
Description
Technical field
The present invention relates to urine gelsolin and its new application of polypeptide fragment, and in particular to urine gelsolin and
Application of its polypeptide fragment in adenocarcinoma of lung diagnosis and treatment.
Background technology
Lung cancer is one of incidence and the highest tumour of the death rate in global range.The WHO recent statistics display whole world is annual
Lung cancer is died of by 1,590,000 patients.Lung cancer can be divided into Small Cell Lung Cancer (small lung cancer, SCLC) by histological type
With non-small cell lung cancer (non-small lung cancer, NSCLC), wherein NSCLC is divided into squamous carcinoma, gland cancer, maxicell again
Cancer, carcinoma sarcomatodes etc..According to driving gene there are situation, and it is squamous carcinoma NSCLC points as what lung cancer was studied deepens continuously
Mainly just refer to adenocarcinoma of lung with non-squama non-small cell lung cancer, rather than squama non-small cell lung cancer.The prognosis of adenocarcinoma of lung is poor, life in 5 years
Rate only 15% is deposited, this is related with to the limited treatment means of metastatic disease mainly due to late diagnosis.At present for lung gland
The early detection of cancer is hindered be subject to following several factors：First, there is no specific clinical symptoms early stage disease；Second,
Patients with lung adenocarcinoma it is older, aggressiveness Results are limited, and patient acceptance is poor；3rd, low-dose spiral CT false positive
Rate is high and expensive, is not suitable for extensive examination.In addition, radioactive exposure may increase lung-cancer-risk.Still lack sensitivity at present
It is used for the relevant biomarker of adenocarcinoma of lung diagnosis and treatment with what specificity was satisfied with.
The structure of gelsolin (Gelsolin, GSN) includes 6 domains, i.e. G1-G6, is that a kind of calcium ion relies on
Property microfilament cutting and add emit albumen.The gene for encoding this albumen is located at No. 9 chromosomes of people.Gelsolin has two kinds to deposit
In form：Secreting type and intracellular type, the molecular weight (83KDa) secreted in blood plasma are bigger than intracellular type (89KDa).In cell
Gelsolin be primarily involved in the assembling of microfilament and go to assemble, the gelsolin in blood be primarily involved in form flesh move egg
White removing system.Gelsolin participates in various physiological processes, such as：Apoptosis, phagocytosis, signal transduction, transcription co-activating etc., institute
Can all find the change of gelsolin expression in many diseases.Some researches show that in interstitial pneumonia, heart disease bag
Kytoplasm gelsolin (cGSN) expression rise in heart failure and oxidative stress and the cell and tissue of many agings is included, but in many
CGSN expression reduces in cancer；Secreting type gelsolin (pGSN) is in acute liver damage, miocardial infarction, infectious shock, muscle
Necrosis, acute respiratory distress syndrome, expressing in experimental acute lung injury and stem cell transplantation reduces, in familial amyloid
Venereal disease becomes and rise is expressed in juvenile's multiple sclerosis.There is the amyloidosis of pancreas islet in the pathologic, physiologic of diabetes
Property, gelsolin plays a role in the amyloidosis of pancreas islet.Gelsolin albumen combines for a kind of actin
Albumen, can recombinate actin filament, participate in cytoskeleton and form, in signal transduction, cell movement, even Apoptosis, tumour
Adjusting of generation etc. plays an important role.Expression of the Gelsolin in the cell cytosols such as breast cancer, stomach cancer, carcinoma of urinary bladder
Amount significantly reduces, and increase is expressed in oophoroma, adenocarcinoma of endometrium, breast cancer, the carcinoma of the rectum, lung cancer, liver cancer
One of the end-product of urine as body metabolism, leave and take with a large amount of property, non-invasive, extensive repeated sampling,
Preserve the unique advantage such as convenient.The change of the composition of urine, quantity and character can reflect the overall metabolism state of body, to grind
Study carefully organ function, evaluation fuselage state, metabolic condition, dynamic monitoring progression of disease and judge that curative effect etc. provides various letters
Breath.If a kind of woundless testing method that early detection is carried out to patients with lung adenocarcinoma can be established, to its examination, diagnosis, prevention
And treatment is respectively provided with extremely important meaning.
The content of the invention
Colloidal sol (Gelsolin, GSN) albumen is coagulated it is an object of the invention to provide a kind of urine and its polypeptide fragment is being made
The application being ready for use in the preparation of detection or auxiliary diagnosis adenocarcinoma of lung.
Preferably, the amino acid sequence of the urine gelsolin such as SEQ ID NO：(MAPHRPAPAL shown in 1
LCALSLALCA LSLPVRAATA SRGASQAGAP QGRVPEARPN SMVVEHPEFL KAGKEPGLQI WRYEKFDLVP
VPTNLYGDFF TGDAYVILKT VQLRNGNLQY DLHYWLGNEC SQDESGAAAI FTVQLDDYLN GRAVQHREVQ
GFESATFLGY FKSGLKYKKG GVASGFKHVV PNEVVVQRLF QVKGRRVVRA TEVPVSWESF NNGDCFILDL
GNNIHQWCGS NSNRYERLKA TQVSKGIRDN ERSGRARVHV SEEGTEPEAM LQVLGPKPAL PAGTEDTAKE
DAANRKLAKL YKVSNGAGTM SVSLVADENP FAQGALKSED CFILDHGKDG KIFVWKGKQA NTEERKAALK
TASDFITKMD YPKQTQVSVL PEGGETPLFK QFFKNWRDPD QTDGLGLSYL SSHIANVERV PFDAATLHTS
TAMAAQHGMD DDGTGQKQIW RIEGSNKVPV DPATYGQFYG GDSYIILYNY RHGGRQGQII YNWQGAQSTQ
DEVAASAILT AQLDEELGGT PVQSRVVQGK EPAHLMSLFG GKPMIIYKGG TSREGGQTAP ASTRLFQVRA
NSAGATRAVE VLPKAGALNS NDAFVLKTPS AAYLWVGTGA SEAEKTGAQE LLRVLRAQPV QVAEGSEPDG
FWEALGGKAA YRTSPRLKDK KMDAHPPRLF ACSNKIGRFV IEEVPGELMQ EDLATDDVML LDTWDQVFVW
VGKDSQEEEK TEALTSAKRY IETDPANRDR RTPITVVKQG FEPPSFVGWF LGWDDDYWSV DPLDRAMAEL
AA)。
Preferably, the GSN albumen and its polypeptide fragment come from urine.
Preferably, the preparation is patients with lung adenocarcinoma GSN albumen and its polypeptide fragment detection kit.The kit bag
The solid phase binding thing and reagent for including box body and being arranged in box body.
Preferably, the solid phase binding thing is microwell plate or magnetic particle, is coated with anti-human GSN albumen and its polypeptide fragment and resists
Body.
Preferably, the reagent includes GSN albumen and its polypeptide fragment standard solution, ELIAS secondary antibody, nitrite ion, termination
Liquid, dilution and cleaning solution.
Inventor have collected the random urine specimen of adenocarcinoma of lung and normal control first, and supernatant is taken after centrifugation, utilize weak sun
Ion exchange magnetic beads for purifying and separated urine sample.By 1 μ l samples and 10 μ l matrix (0.3% alpha-cyano -4- hydroxy cinnamates
Acid, HCCA) mix after, take 1 μ l points on Anchorchip (Autoflex MALDI TOF, Bruker-Dalton) target plate, mark
Mass spectral analysis is carried out after this ionization, the data in the range of 1000-10000Da is gathered, obtains by the protein peak of different mass-to-charge ratioes
The mass spectrum polypeptide figure of composition.All mass spectrums using ClinProTools2.1 analysis softwares to adenocarcinoma of lung group and Normal group
Figure is analyzed, and screens otherness polypeptide.Then inventor carries out Matrix-assisted to the otherness polypeptide with statistical significance
Laser desorption ionisation flight time mass spectrum (Matrix-assisted laser desorption ionization time of
Flight mass spectrometry, MALDI-TOF-MS) identification, in International Protein Index (IPI
Human v3.45fasta with 71983entries) database retrieval obtains differential expression between adenocarcinoma of lung group and normal control
GSN albumen, and compared with Normal group, GSN albumen low expression in the urine of patients with lung adenocarcinoma.
The present invention is by studying confirmation compared with Normal group, GSN albumen low table in the urine of adenocarcinoma of lung group patient
Reach, so as to propose that detection urine GSN albumen and its polypeptide fragment can be used for the diagnosis and treatment of adenocarcinoma of lung.
The present invention play urine specimen obtain it is noninvasive, can repeated sampling, the convenient advantage of preservation on a large scale, utilize urine mark
This detection GSN albumen and its polypeptide fragment.
For above and other objects of the present invention, feature and advantage can be become apparent, preferred embodiment cited below particularly,
And coordinate attached drawing, it is described in detail below.
Brief description of the drawings
Fig. 1 is the scatter diagram that GSN albumen is expressed in all samples of adenocarcinoma of lung group and Normal group.
Fig. 2 is GSN albumen in adenocarcinoma of lung group and the peak area distribution map of Normal group.
Fig. 3 is the ROC curve that urine GSN albumen is expressed in adenocarcinoma of lung group.
Fig. 4 is differential expression of the Immunohistochemical detection GSN albumen in control tissue by adenocarcinoma of lung and cancer.
Embodiment
Embodiment 1The collection and processing of urine specimen
Patients with lung adenocarcinoma 34 (Beijing Shijitan Hospital, CMU's division of respiratory disease outpatient service) is collected to clean at random
Mud-stream urine sample, the interior centrifugations (1500rpm, 5min) of 2h, retains supernatant.- 80 DEG C of refrigerators freeze after packing.Normal group is
36 (Beijing Shijitan Hospital, CMU's medical centers).Specifically it refer to table 1 below：
The clinical data that 1. 2 groups of table
Embodiment 2Polypeptide in magnetic beads for purifying and separated urine sample
Urine specimen is taken out from -80 DEG C of refrigerators, 4 DEG C melt again, take supernatant spare after centrifugation (3000rpm, 10min).Room temperature
Lower balance weak cation magnetic bead (MB-WCX), and bead suspension is mixed manually.In sample cell add 10ul MB-WCX and
10ul magnetic bead combination buffers, sample loading gun blow and beat mixing up and down, avoid blistering.5ul urine supernatants are added into sample cell, fully
1 minute is stood on magnetic frame after mixing, magnetic bead is separated with the liquid to suspend.The clear liquid to suspend, pipette tips are removed with sample loading gun
Magnetic bead should be avoided contact to, avoids siphoning away magnetic bead.100ul magnetic bead cleaning buffer solutions are added in sample cell, will after fully mixing
Sample cell stands 1 minute on magnetic frame, and magnetic bead is adherent, is separated with the liquid of suspension, and the liquid to suspend is removed with sample loading gun.Weight
It is 3 times multiple, discard suspension.5ul magnetic bead elution buffers are added in sample cell, inhales and makes a call to more than 10 times repeatedly, make magnetic bead and wash
De- buffer solution mixes, and avoids blistering.Sample cell is positioned on magnetic frame, 2min is stood, magnetic bead is sufficiently separated with suspension,
Supernatant (eluent) is moved into marked new 0.5ml sample cells.5ul stabilizing buffers are added, sample loading gun is carefully blown and beaten
Mix.
Embodiment 3The point target of urine specimen and polypeptide spectrum map generalization
After being rectified an instrument with standard items, by 1 μ l eluents and 10 μ l matrix (0.3% alpha-cyano -4- hydroxycinnamic acids,
HCCA) mix, taking 1 μ l points, room temperature is done on Anchorchip (Autoflex MALDI TOF, Bruker-Dalton) target plate
It is dry.Sample is carried out mass spectral analysis after ionizing by nitrogen laser irradiation, gather the data in the range of 1000-10000Da, obtain
Obtain the mass spectrogram being made of the protein peak of different mass-to-charge ratioes.For each MALDI crystalline temperature, 400 laser of concurrent irradiation
(respectively irradiation 50 times of 8 different positions of each crystalline temperature), average value represents a sample, so as to obtain the more of all samples
Peptide mapping.The mass spectrogram of Normal group and adenocarcinoma of lung group is analyzed using ClinProTools2.1 analysis softwares, is screened
Otherness polypeptide.Screening conditions：Mass range 1000-10000Da, signal-to-noise ratio (S/N) are more than 5, and Mass Drift is no more than
0.1%, all mass spectrograms are normalized according to total ion current.2 polypeptide fragments of GSN albumen are suffered from normal person and adenocarcinoma of lung
It can be detected in the urine of person, and confirm GSN albumen low expression in patients with lung adenocarcinoma urine.Peak area is as quantitative
Standard, the normality of Anderson-Darling check analysis data, t examine the continuous data for being used for analyzing normal distribution,
Wilcoxon examines the continuous data for being used for analyzing Non-Gaussian Distribution.P ＜ 0.05 are thought with significant difference.
Embodiment 4The identification of differential peptides
Magnetic bead eluent rotation in sample cell is evaporated, add 20ul mobile phase As (5% acetonitrile, 0.1% formic acid it is water-soluble
Liquid) dissolving, it is transferred in sample injection bottle.Sampling volume 18ul, enters trapping column desalination with the speed of 15 μ l/min first, during trapping
Between 3min.Then analytical column is entered with the flow velocity of 400nl/min and carries out gradient elution, gradient 5%B-50%B-80%
B-80%B-50%B-5%B (Mobile phase Bs：2) 95% acetonitrile, the aqueous solution of 0.1% formic acid, is shown in Table.Analysis time 60min, color
35 DEG C of column temperature is composed, all elution components enter spectrometer analysis.Nano ion guns, spray voltage 1.8kV；Mass spectrum pattern is number
Excluded according to dependence and dynamic, scanning range 400-2000m/z；Level-one scanning (MS) uses Obitrap, and resolution setting is
100000；CID and two level scanning use LTQ；The single isotope conduct of 10 most strong ions of intensity is chosen in MS spectrograms
Parent ion carries out MS/MS (single electric charge excludes, not as parent ion).Scanning of the mass spectrum time 60min.Using Data Analysis Software
BioworksBrowser 3.3.1SP1 carry out SequestTMRetrieval.Searching database is International Protein
Index(IPI human v3.45fasta with 71983entries).Parent ion error is set as 100ppm, fragment ion
Error is set to 1Da, and digestion mode is non-digestion, it is variable be modified to it is methionine oxidized.Retrieval result parameter setting is deltacn
>=0.10, two electric charge Xcorr2.6, tricharged Xcorr 3.1, tricharged above Xcorr 3.5.Retrieval obtains in the database
The GSN albumen of adenocarcinoma of lung group and Normal group differential expression, and compared with Normal group, GSN albumen is suffered from adenocarcinoma of lung
Low expression in the urine of person.
The program of 2 analytical column gradient elution of table
Embodiment 5Immunohistochemistry verification of the GSN albumen in normal control and patients with lung adenocarcinoma tissue
Control tissue sample by paraffin embedding adenocarcinoma of lung and cancer is cut into 4-mm sections, glass slide is dewaxed with dimethylbenzene
20min, 100%, 100%, 95% and 75% Gradient elution using ethanol, 2min/ times.After phosphate buffer (PBS) rinsing 10min
Carry out antigen retrieval, 3%H2O215min is incubated, PBS rinsing 10min, add mouse anti human alpha1 Anti-trypsin monoclonal antibody
It is incubated, PBS washings, adds 37 DEG C of incubation 20min, PBS washing 15min of secondary antibody of horseradish peroxidase-labeled.Chromogen 3,
3 '-diaminobenzidine solution dyes 5min, and the ethanol gradient of haematoxylin redyeing 2min, 75%, 95%, 100%, 100% takes off
Water, dimethylbenzene clean and use natural gum mounting, and micro- Microscopic observation is as a result, concrete outcome please refer to Fig. 4.From figure substantially
Go out, GSN albumen expresses notable downward in the tissue of patients with lung adenocarcinoma.
Embodiment 6Measure the GSN protein contents in patients with lung adenocarcinoma urine
Anti-human GSN fusion proteins antibody is diluted with coating buffer solution, is added it on solid phase binding thing, 4 DEG C
Coating is overnight.Not coated liquid is removed, is washed 3 times with PBST, 200ul retardance liquid is added and prevents nonspecific binding site,
When 37 DEG C of incubations 1 are small, PBST is eluted 3 times.4 DEG C are put into save backup.
Take patients with lung adenocarcinoma (Beijing Shijitan Hospital, CMU) cleaning stage casing random urine 30- to be measured
50ml, loads clean urinary catheter, and when women preserving urine sample should avoid menstrual period, vaginal fluid should be prevented to be mixed into urine, often
The lower 1500rpm of temperature is centrifuged 5 minutes, takes supernatant to be checked.
Quantitative GSN gene recombinant proteins are purified as standard items, sample to be measured is added to the solid phase knot being coated with
In compound, when 37 DEG C of incubations 1 are small, uncombined antigen is washed away with board-washing liquid PBST, blots residual liquid.Add ELIAS secondary antibody,
37 DEG C are incubated 30 minutes, and PBST is washed 4 times, blots residual liquid.Nitrite ion is added, room temperature is placed 10 minutes, utilizes computer
Read the content of GSN albumen in sample.
In this way, inventor have detected containing for GSN albumen in patient's random urines of 50 diabetes and coronary heart diseases
Amount, and describe ROC curve, sensitivity and the specificity for reacting the albumen are preferable.
Although the present invention is disclosed as above with preferred embodiment, so it is not limited to the present invention, any affiliated technology
The technical staff in field, without departing from the spirit and scope of the present invention, when can make a little change with improve, therefore the present invention
Protection domain when regard as defined in claim subject to.
Claims (8)
1. urine gelsolin (GSN) and its polypeptide fragment are being prepared for detecting and answering in auxiliary diagnosis adenocarcinoma of lung preparation
With.
2. application according to claim 1, it is characterised in that the amino acid sequence of the urine GSN albumen such as SEQ ID
NO：Shown in 1.
3. application according to claim 1, it is characterised in that the GSN albumen and its polypeptide fragment come from urine.
4. application according to claim 1, it is characterised in that the preparation is patients with lung adenocarcinoma urine GSN albumen and its more
Fragments of peptides detection kit.
5. application according to claim 4, it is characterised in that the kit includes box body and is arranged in box body
Solid phase binding thing and reagent.
6. application according to claim 5, it is characterised in that the solid phase binding thing is microwell plate or magnetic particle.
7. application according to claim 6, it is characterised in that be coated with microwell plate or magnetic particle anti-human GSN albumen and its
Polypeptide fragment antibody.
8. application according to claim 5, it is characterised in that the reagent includes GSN albumen and its polypeptide fragment standard
Product solution, ELIAS secondary antibody, nitrite ion, terminate liquid, dilution and cleaning solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610952044.3A CN108020663A (en) | 2016-11-02 | 2016-11-02 | The application of urine gelsolin and its polypeptide fragment in adenocarcinoma of lung |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610952044.3A CN108020663A (en) | 2016-11-02 | 2016-11-02 | The application of urine gelsolin and its polypeptide fragment in adenocarcinoma of lung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108020663A true CN108020663A (en) | 2018-05-11 |
Family
ID=62070090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610952044.3A Pending CN108020663A (en) | 2016-11-02 | 2016-11-02 | The application of urine gelsolin and its polypeptide fragment in adenocarcinoma of lung |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108020663A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112057465A (en) * | 2020-08-03 | 2020-12-11 | 暨南大学 | Application of 3' UTR of GSN mRNA in preparing antitumor drugs |
| CN113092772A (en) * | 2019-12-23 | 2021-07-09 | 首都医科大学附属北京世纪坛医院 | Application of urine cadherin subgroup SA-2 and polypeptide fragment thereof in allergic diseases |
| CN113917149A (en) * | 2021-09-30 | 2022-01-11 | 江苏扬新生物医药有限公司 | Application of gelsolin detection substance in preparation of uterine cancer evaluation detection reagent |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102119173A (en) * | 2007-08-15 | 2011-07-06 | 北京同为时代生物技术有限公司 | Gelsolin binding agent compositions and uses of same |
-
2016
- 2016-11-02 CN CN201610952044.3A patent/CN108020663A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102119173A (en) * | 2007-08-15 | 2011-07-06 | 北京同为时代生物技术有限公司 | Gelsolin binding agent compositions and uses of same |
Non-Patent Citations (6)
| Title |
|---|
| A.M.RODRIGUEZ-PINEIRO等: "On the identification of biomarkers for non-small cell lung cancer in serum and pleural effusion", 《JOURNAL OF PROTEOMICS》 * |
| HIROTOSHI DOSAKA-AKITA等: "Frequent loss of gelsolin expression in non-small cell lung cancers of heavy smokers", 《CANCER RESEARCH》 * |
| STRAUSBERG,R.L.等: "GenBank: AAH26033.1 Gelsolin (amyloidosis, Finnish type) [Homo sapiens]", 《GENBANK》 * |
| 孙明飞 等: "肺腺癌相关蛋白初步筛选及鉴定", 《河南大学学报（医学版）》 * |
| 孙明飞: "肺腺癌肿瘤标志物初步筛选及鉴定", 《中国优秀硕士学位论文全文数据库》 * |
| 张渊: "非小细胞肺癌患者尿液中潜在生物标志物的研究", 《中国博士学位论文全文数据库》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113092772A (en) * | 2019-12-23 | 2021-07-09 | 首都医科大学附属北京世纪坛医院 | Application of urine cadherin subgroup SA-2 and polypeptide fragment thereof in allergic diseases |
| CN112057465A (en) * | 2020-08-03 | 2020-12-11 | 暨南大学 | Application of 3' UTR of GSN mRNA in preparing antitumor drugs |
| CN113917149A (en) * | 2021-09-30 | 2022-01-11 | 江苏扬新生物医药有限公司 | Application of gelsolin detection substance in preparation of uterine cancer evaluation detection reagent |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019205010B2 (en) | Multiplex biomarker for use in evaluation of state of accumulation of amyloid B in brain, and analysis method for said evaluation | |
| US8389222B2 (en) | Apolipoprotein fingerprinting technique and methods related thereto | |
| WO2023082821A1 (en) | Serum metabolism marker for diagnosing benign and malignant pulmonary nodules and use thereof | |
| CN108020663A (en) | The application of urine gelsolin and its polypeptide fragment in adenocarcinoma of lung | |
| CA2705952A1 (en) | Methods for detecting lung cancer and monitoring treatment response | |
| WO2023083197A1 (en) | Metabolic marker for diagnosing or monitoring lung cancer, and screening method therefor and use thereof | |
| CN108020669A (en) | Application of the urine osteopontin polypeptides fragment in adenocarcinoma of lung | |
| CN108020667A (en) | The application of urine immunoglobulin kappa chain C area's albumen and its polypeptide fragment in adenocarcinoma of lung | |
| CN108020668B (en) | The application of 3 albumen of urine SH3 structural domain glutamic acid rich sample albumen and its polypeptide fragment in adenocarcinoma of lung | |
| CN114924073B (en) | Tumor diagnosis marker combination in colorectal progression stage and application thereof | |
| Liu et al. | Potential biomarkers for esophageal carcinoma detected by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry | |
| CN108646032A (en) | Purposes of the TOP2A autoantibodies as pulmonary cancer diagnosis marker | |
| EP2894477A1 (en) | Method for determining breast cancer | |
| WO2013016965A1 (en) | Mass spectrum model for detecting characteristic proteins of type i diabetes and construction method thereof | |
| CN107102152B (en) | The protein marker of urine myocardial infarction and its purposes in diagnosis and prognosis | |
| CN111273023B (en) | Lung adenocarcinoma tumor marker protein and application thereof | |
| Hu et al. | A primary proteomic analysis of serum from patients with nonfunctioning pituitary adenoma | |
| US20090280512A1 (en) | Tumor marker for renal cancer and method for determination of occurrence of renal cancer | |
| WO2016127278A1 (en) | Application of urine complement component 3 (c3) protein | |
| EP2322935B1 (en) | Method for evaluating myocardial ischemic state using blood sample | |
| CN108020670B (en) | Application of the variable region the urine immunoglobulin κ 4-1 albumen in adenocarcinoma of lung | |
| CN108020671B (en) | Application of the urine IGKV2-28 albumen in adenocarcinoma of lung | |
| CN104714020B (en) | Urine endogenous α trypsin inhibitor heavy chain H4 merges the application in coronary heart disease at diabetes B | |
| CN104714022B (en) | The application in type 2 diabetes mellitus merges coronary heart disease of the urine Fibrinogen α chain | |
| CN116519952B (en) | Marker for pre-operation screening and diagnosis of carotid aneurysm and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180511 |